GAMMA Investing LLC Has $4.52 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 7,486.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 53,864 shares of the medical instruments supplier's stock after acquiring an additional 53,154 shares during the quarter. GAMMA Investing LLC owned 0.24% of LeMaitre Vascular worth $4,519,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of LMAT. Smartleaf Asset Management LLC boosted its position in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 293 shares during the period. CBIZ Investment Advisory Services LLC grew its holdings in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 117 shares in the last quarter. Huntington National Bank boosted its holdings in LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after purchasing an additional 455 shares in the last quarter. Empowered Funds LLC bought a new stake in LeMaitre Vascular during the fourth quarter valued at about $150,000. Finally, Canada Pension Plan Investment Board lifted its stake in shares of LeMaitre Vascular by 112.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock valued at $157,000 after buying an additional 900 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 0.3%

Shares of LMAT traded down $0.24 during mid-day trading on Friday, hitting $81.13. 229,261 shares of the company's stock were exchanged, compared to its average volume of 169,218. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The stock's 50-day simple moving average is $83.86 and its 200-day simple moving average is $90.29. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 44.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same quarter in the previous year, the firm posted $0.44 earnings per share. The firm's quarterly revenue was up 12.0% on a year-over-year basis. Analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.99%. LeMaitre Vascular's dividend payout ratio is currently 40.40%.

Analyst Ratings Changes

LMAT has been the subject of several recent analyst reports. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Lake Street Capital boosted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $97.83.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 76,868 shares of the business's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $85.79, for a total value of $6,594,505.72. Following the sale, the chief executive officer now owns 1,796,783 shares of the company's stock, valued at $154,146,013.57. The trade was a 4.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 100,000 shares of company stock valued at $8,556,857. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.